We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+18.53%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.06B
AUM Growth
+$54.1M
Cap. Flow
-$57.6M
Cap. Flow %
-5.46%
Top 10 Hldgs %
34.88%
Holding
95
New
10
Increased
31
Reduced
41
Closed
11

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$29.7M
2
ELV icon
Elevance Health
ELV
+$28.1M
3
BDX icon
Becton Dickinson
BDX
+$27.8M
4
PEN icon
Penumbra
PEN
+$10.8M
5
MRK icon
Merck
MRK
+$8.75M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$22.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$18.7M
3
HUM icon
Humana
HUM
+$17.9M
4
LLY icon
Eli Lilly
LLY
+$17M
5
PFE icon
Pfizer
PFE
+$16.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Industrials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
26
Align Technology
ALGN
$12.5B
$16.4M 1.55%
50,000
+23,000
+85% +$6.75M
DVAX
27
DELISTED
Dynavax Technologies
DVAX
$14.4M 1.36%
1,157,361
+357,361
+45% +$4.66M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$2.9B
$14.2M 1.34%
955,000
-161,818
-14% -$1.88M
CYTK icon
29
Cytokinetics
CYTK
$10.5B
$13.8M 1.31%
197,515
+47,603
+32% +$3.68M
BIIB icon
30
Biogen
BIIB
$30.6B
$12.2M 1.16%
56,800
-1,872
-3% -$438K
VKTX icon
31
Viking Therapeutics
VKTX
$4.02B
$11.9M 1.13%
145,000
-35,000
-19% -$1.56M
AXSM icon
32
Axsome Therapeutics
AXSM
$11.4B
$11.5M 1.09%
143,600
+64,500
+82% +$5.41M
APLS
33
DELISTED
Apellis Pharmaceuticals
APLS
$10.5M 0.99%
178,395
+77,995
+78% +$4.97M
COR icon
34
Cencora
COR
$62B
$10.3M 0.98%
42,500
-53,500
-56% -$12.3M
PEN icon
35
Penumbra
PEN
$12.8B
$10.3M 0.97%
46,000
+43,500
+1,740% +$10.8M
CNC icon
36
Centene
CNC
$32.9B
$10.1M 0.96%
129,000
-6,000
-4% -$463K
ALHC icon
37
Alignment Healthcare
ALHC
$2.86B
$10M 0.95%
2,022,736
+1,072,736
+113% +$6.87M
EXAS
38
DELISTED
Exact Sciences
EXAS
$9.88M 0.94%
143,000
-22,000
-13% -$1.39M
MDGL icon
39
Madrigal Pharmaceuticals
MDGL
$11.9B
$9.75M 0.92%
36,500
+14,000
+62% +$3.3M
ITCI
40
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.52M 0.9%
137,500
+47,500
+53% +$3.26M
GILD icon
41
Gilead Sciences
GILD
$165B
$9.3M 0.88%
127,000
-132,000
-51% -$10.2M
INSP icon
42
Inspire Medical Systems
INSP
$1.73B
$9.02M 0.86%
42,000
+24,000
+133% +$4.7M
ZBH icon
43
Zimmer Biomet
ZBH
$18.7B
$8.91M 0.84%
67,500
+12,500
+23% +$1.56M
NBIX icon
44
Neurocrine Biosciences
NBIX
$16.8B
$8.14M 0.77%
59,000
-3,000
-5% -$410K
IQV icon
45
IQVIA
IQV
$39.8B
$7.84M 0.74%
31,000
-14,000
-31% -$3.27M
NVCR icon
46
NovoCure
NVCR
$2.02B
$7.74M 0.73%
495,307
+335,307
+210% +$4.93M
EPIX
47
DELISTED
ESSA Pharma
EPIX
$7.74M 0.73%
911,820
+555,320
+156% +$4.85M
TMO icon
48
Thermo Fisher Scientific
TMO
$222B
$7.56M 0.72%
13,000
-20,500
-61% -$11.5M
ARVN icon
49
Arvinas
ARVN
$588M
$7.02M 0.67%
170,000
+35,730
+27% +$1.56M
NUVL
50
DELISTED
Nuvalent
NUVL
$6.57M 0.62%
87,500
-25,429
-23% -$2.02M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rhenman & Partners Asset Management held 95 positions worth $1.06B, up 5.4% from $1B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $57.6M in Q1 2024, closing 11 positions and reducing 41 holdings. Its most notable exit was Humana, an estimated $17.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Becton Dickinson worth $28.7M.

  • Rhenman & Partners Asset Management's largest Q1 2024 buy was Becton Dickinson: 116,000 shares worth $28.7M.
  • Rhenman & Partners Asset Management added most to Cigna in Q1 2024, an estimated $29.7M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2024 reduction was Medtronic, cutting an estimated $22.7M.
  • Rhenman & Partners Asset Management fully exited Humana in Q1 2024, selling an estimated $17.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.06B portfolio in Q1 2024.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 11 in Q1 2024.
  • Rhenman & Partners Asset Management's portfolio value rose 5.4% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2024, filed 14 May 2024.